Other research highlights: 30% of GLP-1 users tested positive for SIBO or IMO even after accounting for diabetes (5) GLP-1 medicines caused microbiome changes and altered metabolism in mice (6) GLP-1 medicines tested in humans only had noticeable microbiome changes by 48 weeks (7) Despite not necessarily having slower gut motility, one study found that 88.9% of obese patients had SIBO (8) A meta analysis of people with IBS symptoms, found that up to 78% of people had SIBO, many of whom were undiagnosed (9) Overall, Sun and colleagues (1) could not prove a mechanistic link between GLP-1 medications and SIBO, however they did find that SIBO was twice as likely in GLP-1 users
These results suggest that not all diabetes medicines provide the same brain benefits
As obesity continues to pose a global health crisis, approaches targeting brain regulators of appetite and metabolism are increasingly central
Laboratory parameters assessed at baseline and at 6 months included liver function tests [aspartate aminotransferase (AST), alanine aminotransferase (ALT), and -glutamyltransferase (GGT)], lipid profile [total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides], HbA1c, and FBG
Get expert fertility care in the UK, via Amilis Frequently asked questions In an eggshell